Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - phleum pratense, quantity: 75000 sq-t - tablet - excipient ingredients: gelatin; mannitol; sodium hydroxide; purified water - grazax is indicated for disease modifying treatment of grass pollen (phleum pratense or allergens cross reacting with p. pratense) induced allergic rhinitis with or without conjunctivitis in adults, adolescents and children above the age of 5 years.

Ireland - English - HPRA (Health Products Regulatory Authority)

ayrton saunders ltd - iodinated povidone - cutaneous solution - 100 milligram(s)/millilitre - iodine products; povidone-iodine

Australia - English - Department of Health (Therapeutic Goods Administration)

universal pharmaceuticals pty ltd - apium graveolens,choline bitartrate,centella asiatica,ginkgo biloba -

Ireland - English - HPRA (Health Products Regulatory Authority)

mundipharma pharmaceuticals limited - iodinated povidone - cutaneous solution - 100 milligram(s)/millilitre - iodine products; povidone-iodine

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

delfi marketing sdn.bhd. - standardised extract (panax ginseng); ginkgo biloba extract -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - piperacillin sodium, quantity: 4.253 g; tazobactam sodium, quantity: 0.547 g (equivalent: tazobactam, qty 0.5 g) - injection, powder for - excipient ingredients: - pipertaz sandoz is used to treat serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: 1) lower respiratory tract infections; 2) urinary tract infections (complicated and uncomplicated); 3) intra-abdominal infections; 4) skin and skin structure infections; 5) bacterial septicaemia; 6) gynaecological infections. children under the age of 12 years: in hospitalised children aged 2 to 12 years, pipertaz sandoz is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in children below the age of 2 years. while pipertaz sandoz (piperacillin/tazobactam) is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing, piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to det

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - sodium selenite; copper sulfate anhydrous; folic acid; ascorbic acid; nicotinamide; biotin; cyanocobalamin; pyridoxine hydrochloride; riboflavin; thiamine nitrate; alpha tocopheryl acetate; colecalciferol; ginseng standardised extract; magnesium sulfate dried; vitamin a palmitate; lecithin; calcium hydrogen phosphate anhydrous; zinc sulfate monohydrate; ferrous sulfate dried - oral capsule - 50microgram ; 2mg ; 100microgram ; 60mg ; 18mg ; 150microgram ; 1microgram ; 2mg ; 1.6mg ; 1.4mg ; 10mg ; 200unit ; 40mg ; 10mg ; 2667unit ; 100mg ; 100mg ; 1mg ; 10mg

Ireland - English - HPRA (Health Products Regulatory Authority)

alk-abello a/s - grass pollen extract (phleum pratense) - sublingual lyophilisate - 75, 000 standardised quality units tablet - allergen extracts; grass pollen

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - piperacillin sodium, quantity: 4170 mg (equivalent: piperacillin, qty 4000 mg); tazobactam sodium, quantity: 540 mg (equivalent: tazobactam, qty 500 mg) - injection, powder for - excipient ingredients: nitrogen - piptaz-aft is indicated in the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated) 3. intra-abdominal infections 4. skin and skin structure infections 5. bacterial septicaemia 6. gynaecological infections,children under the age of 12 years in hospitalised children aged 2 to 12 years, piptaz-aft is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years. while piptaz-aft is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing, piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibilities to piptaz-aft. therapy with piptaz-aft, however, may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above; however, once these results become available, appropriate therapy should be continued. in serious infections, presumptive therapy with piptaz-aft may be initiated before susceptibility test results are available. combination therapy with piptaz-aft and aminoglycosides may be used in the treatment of serious infections caused by pseudomonas aeruginosa. both drugs should be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.

Australia - English - Department of Health (Therapeutic Goods Administration)

mms international health products pty ltd - tanacetum parthenium -